30 closest matches · ranked by relevance
Chronic Kidney Disease · Secondary Hyperparathyroidism
Primary: Achievement of a ≥ 30% Reduction in Mean PTH From Baseline to During the Efficacy Assessment Phase at Month 6 (Weeks 22 to 26) — 96; 58; 57; 93 participants — p=<0.0001
Kidney Failure · End Stage Renal Disease · Hypotension
Primary: Dialysis Session Stability — 0.202; 0.199; 0.172; 0.182 Proportion of sessions
End Stage Renal Disease
Primary: First Catheter Induced Complication — 78; 77 percentage of participants
Secondary Peritonitis
Primary: Peritonitis Resolved — 26; 29 participants — p=<0.05
Arrhythmias, Cardiac
Primary: Number of Participants With a Significant Arrhythmia Detected — 0 participants
Dialysis; Complications · Life Quality
Primary: Post-dialysis Recovery Time — 278.02 minutes
End Stage Renal Disease
Primary: Serum 25D Level — 49.8; 38.3; 27.3 ng/ml
Intra-dialytic Hypotension
Primary: Efficacy of Mannitol Administration in Reducing the Frequency of Intra-dialytic Hypotension (Decline in Systolic Blood Pressure) During the First Three Hemodialysis…
Hyperkalemia
Primary: Incidence of Pre-dialysis HK After the LIDP in <3K Dialysate Patients — 50; 37 Percent of participants
Acute Kidney Injury
Primary: Acute Kidney Injury — 110; 190; 122; 88 Participants
Acute Kidney Injury
Primary: Mortality — 96; 34 Participants — p=<0.0001
Acute Kidney Injury
Primary: Number of Participants With Negative Fluid Balance on Postop Day 1 — 21; 29 Participants
Critically Ill · Hemodialysis
Primary: Daptomycin Transmembrane Clearance by Continuous Venovenous Hemodialysis — 6.3 mL/min
Improve Endothelial Function and Decrease Vascular Stenosis
Primary: Change in Baseline and 2 Week FMD/VP Measurements Between Sildenafil Group and Placebo Group — 10.8; 8.6 Change in FMD%
End Stage Renal Disease
Primary: Peridialytic Arterialized Blood Bicarbonate Concentrations — 25.7; 27.1; 27.2; 27.4 mEq/l — p=<0.0001
Dialysis Related Complication · Dialysis Hypotension · Hemodialysis-Induced Symptom
Primary: Medium Molecule Clearance — 53; 59.5 ml/min — p=0.4534
End Stage Renal Disease · Infection
Primary: Intradialytic Clearance of Levofloxacin, Gentamicin and Vancomycin in Patients Receiving Short-daily Hemodialysis — 7.2; 7.6 ml/min
End Stage Renal Disease
Primary: Number of Participants With Clinically Significant Cardiac Arrhythmias Using Continuous Cardiac Monitoring Over a 6-month Period With an Implanted Medtronic Reveal ICM…
Diabetes Type 2
Primary: Hemoglobin A1c Levels — 7.1; 7.1 percent — p=0.67
Intra-dialytic Hypotension
Primary: Change in Intra-dialytic Decline in Systolic Blood Pressure — 26; 23 mm Hg
Hypertension · Renal Failure Chronic Requiring Hemodialysis · Blood Pressure
Primary: Number of Participants Assessed for Intensive (110-140 mm Hg) and Standard (155-165mm Hg) Pre-dialysis Standardized BP Goal — 62; 64 participants
End Stage Renal Disease · Chronic Kidney Diseases
Primary: Mean Feasibility of Intervention Measure — 16.4; 16.1; 19.0 score on a scale
Chronic Kidney Failure
Primary: Ease of Use: Priming Blood Side — 139; 13; 13; 80 Number of Dialyzers
End Stage Renal Disease
Primary: High Sensitivity C-reactive Protein (hsCRP) — 4.67; 15.11 mg/dl — p=0.008
End Stage Renal Disease
Primary: Mean Partial Thromboplastin Time (PTT) at 15 Minutes — 38.4; 38.4; 45.4; 49.7 Seconds
End Stage Renal Disease
Primary: Adherence With Proposed Interventions — 88; 90; 83; 80 Percentage of sessions
Chronic Kidney Disease
Primary: Preference for Shared Decision Making — 22; 19; 35; 44 participants
End Stage Renal Disease (ESRD) · Diabetes · CAPD
Primary: Change From the Baseline Value in HbA1c at Month 3 and 6 — 0.2; -0.6; 0; -0.6 Percent Change — p=<0.001
Acute Kidney Failure
Primary: Ertapenem Transmembrane Clearance by Continuous Hemodialysis. — 10.4 mL/min
End Stage Renal Disease
Primary: Reduction Ratio of Lambda Immunoglobulin FLC at Week 24 — 32.156; 17.514 percentage ratio